The STK17A Polyclonal Antibody (PAC012529) is a valuable tool for researchers studying STK17A, a serine/threonine kinase that plays a role in cell cycle regulation and apoptosis. This antibody, produced in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blot applications. By specifically binding to the STK17A protein, this antibody enables the detection and analysis of STK17A in a variety of cell types, making it an ideal choice for studies in cell biology and cancer research.
STK17A, also known as DRAK1, is involved in various cellular processes, including cell proliferation and programmed cell death. Its function in controlling cell growth and survival makes it a key target for investigation in cancer biology and therapeutic development. Understanding the mechanisms by which STK17A impacts cell behavior is essential for advancing our knowledge of cancer progression and identifying new treatment strategies.
DRAK1: a calmodulin-dependent kinase of the DAPK family. Interacts with and is regulated by calcineurin homologous protein (CHP), an EF-hand Ca(2+)-binding protein. In vitro, CHP inhibits the apoptosis-inducing protein kinase DRAK2 in the presence of elevated Ca(2+) levels. Highly expressed in placenta, lung, pancreas. Lower levels in heart, brain, liver, skeletal muscle and kidney.Protein type: Kinase, protein; Protein kinase, CAMK; EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); CAMK group; DAPK familyChromosomal Location of Human Ortholog: 7p13Cellular Component: nucleusMolecular Function: protein serine/threonine kinase activity; ATP bindingBiological Process: apoptosis; positive regulation of apoptosis; protein amino acid phosphorylation
UniProt Protein Details:
NCBI Summary:
This gene is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity. [provided by RefSeq, Jul 2008]